UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 101

Sortiert nach

“A New Hemophilia Carrier Nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH”: Reply to comment

Journal of thrombosis and haemostasis, 2022-07, Vol.20 (7), p.1745-1746

Sidonio, Robert F.

2022

Volltextzugriff (PDF)

Discussing investigational AAV gene therapy with hemophilia patients: A guide

Blood reviews, 2021-05, Vol.47, p.100759-100759, Article 100759

2021

Volltextzugriff (PDF)

Assessment of menstrual health in adolescent and young adults with sickle cell disease

Pediatric blood & cancer, 2024-01, Vol.71 (1), p.e30727-n/a

2024

Volltextzugriff (PDF)

Substitution therapy

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-02, Vol.27 (S3), p.53-59

2021

Volltextzugriff (PDF)

Severe muscle bleeds in children and young adults with hemophilia A on emicizumab prophylaxis: Real-world retrospective multi-institutional cohort

American journal of hematology, 2023-10, Vol.98 (10), p.E285-E287

2023

Volltextzugriff (PDF)

Plasma factor IX: The tip of the iceberg?

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-05, Vol.27 (3), p.329-331

2021

Volltextzugriff (PDF)

Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: A simulation study for individuals with severe haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2024-07, Vol.30 (4), p.905-913

2024

Volltextzugriff (PDF)

Thrombin generation and implications for hemophilia therapies: A narrative review

Research and practice in thrombosis and haemostasis, 2023-01, Vol.7 (1), p.100018-100018, Article 100018

2023

Volltextzugriff (PDF)

Potential Undiagnosed VWD Or Other Mucocutaneous Bleeding Disorder Cases Estimated From Private Medical Insurance Claims

Journal of blood medicine, 2020-01, Vol.11, p.1-11

2020

Volltextzugriff (PDF)

Managing Severe Hemophilia A in Children: Pharmacotherapeutic Options

Pediatric health, medicine and therapeutics, 2022-01, Vol.13, p.27-35

2022

Volltextzugriff (PDF)

International consensus recommendations on the management of people with haemophilia B

Therapeutic Advances in Hematology, 2022, Vol.13, p.20406207221085202-20406207221085202

2022

Volltextzugriff (PDF)

The impact of extended half‐life factor concentrates on prophylaxis for severe hemophilia in the United States

American journal of hematology, 2020-08, Vol.95 (8), p.960-965

2020

Volltextzugriff (PDF)

Characterization of Hysterectomy/Uterine Ablation Rates in VWD and Undiagnosed Bleeding Using Claims Data [32G]

Obstetrics and gynecology (New York. 1953), 2017-05, Vol.129 Suppl 1 (1), p.79S-80S

2017

Volltextzugriff (PDF)

Occurrence rates of von Willebrand disease among people receiving care in specialized treatment centres in the United States

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-05, Vol.27 (3), p.445-453

2021

Volltextzugriff (PDF)

Emicizumab in tolerized patients with hemophilia A with inhibitors: A single‐institution pediatric cohort assessing inhibitor status

Research and practice in thrombosis and haemostasis, 2021-02, Vol.5 (2), p.342-348

2021

Volltextzugriff (PDF)

Bone health in haemophilia carriers and persons with von Willebrand disease: A large database analysis

Haemophilia : the official journal of the World Federation of Hemophilia, 2022-07, Vol.28 (4), p.671-678

2022

Volltextzugriff (PDF)

Design of an international investigator-initiated study on MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A (MOTIVATE)

Therapeutic advances in hematology, 2021, Vol.12, p.20406207211032452-20406207211032452

2021

Volltextzugriff (PDF)

Awareness, Care and Treatment In Obesity maNagement to inform Haemophilia Obesity Patient Empowerment (ACTION‐TO‐HOPE): Results of a survey of US haemophilia treatment centre professionals

Haemophilia : the official journal of the World Federation of Hemophilia, 2020-01, Vol.26 (S1), p.20-30

2020

Volltextzugriff (PDF)

Nanobody activator improves sensitivity of the von Willebrand factor activity assay to multimer size

Journal of thrombosis and haemostasis, 2024-07, Vol.22 (7), p.2052-2058

2024

Volltextzugriff (PDF)

Elevated von Willebrand factor levels during heavy menstrual bleeding episodes limit the diagnostic utility for von Willebrand disease

Research and practice in thrombosis and haemostasis, 2021-05, Vol.5 (4), p.e12513-n/a, Article e12513

2021

Volltextzugriff (PDF)

Simoctocog alfa (Nuwiq ® ) in children: early steps in life's journey for people with severe hemophilia A

Therapeutic advances in hematology, 2024-01, Vol.15, p.20406207241245511-20406207241245511

2024

Volltextzugriff (PDF)

Acquired Hypofibrinogenemia Before Asparaginase Exposure During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia: A Report of 2 Cases and Review of the Literature

Journal of pediatric hematology/oncology, 2018-10, Vol.40 (7), p.e470-e472

2018

Volltextzugriff (PDF)

Women and girls with haemophilia receiving care at specialized haemophilia treatment centres in the United States

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-11, Vol.27 (6), p.1037-1044

2021

Volltextzugriff (PDF)

Procedural outcomes in children with mild type 1 von Willebrand disease

Research and practice in thrombosis and haemostasis, 2024-01, Vol.8 (1), p.102334, Article 102334

2024

Volltextzugriff (PDF)

Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events

Journal of medical economics, 2019-12, Vol.22 (12), p.1328-1337

2019

Volltextzugriff (PDF)

1 – 25 von 101

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(97)
Mit Volltextzugriff
(100)

Publikationsform

Sprache

Englisch
(101)
Portugiesisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

“A New Hemophilia Carrier Nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH”: Reply to comment

Discussing investigational AAV gene therapy with hemophilia patients: A guide

Assessment of menstrual health in adolescent and young adults with sickle cell disease

Substitution therapy

Severe muscle bleeds in children and young adults with hemophilia A on emicizumab prophylaxis: Real-world retrospective multi-institutional cohort

Plasma factor IX: The tip of the iceberg?

Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: A simulation study for individuals with severe haemophilia A

Thrombin generation and implications for hemophilia therapies: A narrative review

Potential Undiagnosed VWD Or Other Mucocutaneous Bleeding Disorder Cases Estimated From Private Medical Insurance Claims

Managing Severe Hemophilia A in Children: Pharmacotherapeutic Options

International consensus recommendations on the management of people with haemophilia B

The impact of extended half‐life factor concentrates on prophylaxis for severe hemophilia in the United States

Characterization of Hysterectomy/Uterine Ablation Rates in VWD and Undiagnosed Bleeding Using Claims Data [32G]

Occurrence rates of von Willebrand disease among people receiving care in specialized treatment centres in the United States

Emicizumab in tolerized patients with hemophilia A with inhibitors: A single‐institution pediatric cohort assessing inhibitor status

Bone health in haemophilia carriers and persons with von Willebrand disease: A large database analysis

Design of an international investigator-initiated study on MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A (MOTIVATE)

Awareness, Care and Treatment In Obesity maNagement to inform Haemophilia Obesity Patient Empowerment (ACTION‐TO‐HOPE): Results of a survey of US haemophilia treatment centre professionals

Nanobody activator improves sensitivity of the von Willebrand factor activity assay to multimer size

Elevated von Willebrand factor levels during heavy menstrual bleeding episodes limit the diagnostic utility for von Willebrand disease

Simoctocog alfa (Nuwiq ® ) in children: early steps in life's journey for people with severe hemophilia A

Acquired Hypofibrinogenemia Before Asparaginase Exposure During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia: A Report of 2 Cases and Review of the Literature

Women and girls with haemophilia receiving care at specialized haemophilia treatment centres in the United States

Procedural outcomes in children with mild type 1 von Willebrand disease

Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events

Aktive Filter

Suchergebnisse filtern